Vasoactive Agents in Pulmonary Hypertension Crisis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective, randomized trial compares three vasoactive drugs—dopamine, norepinephrine, and epinephrine—for treating patients experiencing a pulmonary hypertension crisis. Haemodynamic monitoring guides the assessment of each drug’s safety and effectiveness. Eligible adults with PAH or CTEPH who are in hospital and have not yet received any of the study drugs are randomized to receive one of the agents. The study aims to identify which agent provides the best balance of blood pressure support and oxygen delivery while minimizing adverse events. Conducted at major Chinese centers, the trial emphasizes in-hospital management and continuous safety monitoring.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age \> 18 years old;
2. Signed informed consent form;
3. Confirmed diagnosis of arterial pulmonary hypertension (PAH) and/or chronic thromboembolic pulmonary hypertension (CTEPH);
4. Presenting with manifestations of pulmonary hypertensive crisis;
5. Receiving both diagnosis and treatment in-hospital;
6. No intravenous administration of the vasopressor drugs (including dopamine, norepinephrine, and epinephrine) under study at enrollment.

Exclusion Criteria:

1. At SCAI stage D or stage E ;
2. Patients who only receive a diagnosis but no treatment in the hospital;
3. Uncontrolled hyperthyroidism;
4. Complicated with angle-closure glaucoma;
5. Hypersensitivity to the study drug;
6. Ongoing use of halogenated hydrocarbon general anesthetics such as cyclopropane and halothane;
7. Ongoing use of monoamine oxidase inhibitor (MAOI) antidepressants or anti-Parkinson drugs (phenelzine, tranylcypromine, isocarboxazid, moclobemide);
8. Pregnancy;
9. Already receiving the vasopressor drugs (dopamine, norepinephrine, epinephrine) under study at enrollment.

Where it's running

• Chinese Academy of Medical Sciences, Fuwai Hospital
  Beijing, Beijing Municipality, China Recruiting
• Guangdong Provincial People's Hospital
  Guangzhou, Guangdong, China Not yet recruiting
• Zhongnan Hospital of Wuhan University
  Wuhan, Wuhan, China Not yet recruiting

Study contacts

• Study coordinator: Qing Gu,MD
• Email: guqingfw@126.com
• Phone: +86 010-88392814

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Impact of ambient air vs nasal liquid oxygen on exercise performance in pulmonary vascular disease

  This study tests whether using nasal liquid oxygen during a 6-minute walk test changes how far patients with PAH or CTEPH can walk compared to breathing room air.

  Recruiting University of Zurich · Zurich, Canton of Zurich · NCT07777445

• Liquid oxygen vs ambient air during a 6-minute walk in people with pulmonary vascular disease

  This study tests whether walking with liquid oxygen at about 4 L/min helps or hinders distance walked compared with walking on room air in adults with PAH or CTEPH living in Switzerland.

  Recruiting University of Zurich · Zurich, Canton of Zurich · NCT07777367

• Levosimendan to see if it helps the heart after PEA in CTEPH

  This small randomized trial tests whether giving levosimendan around surgery helps reduce pulmonary artery pressure and support right heart function after pulmonary endarterectomy for CTEPH.

  Recruiting Meshalkin Research Institute of Pathology of Circulation · Novosibirsk · NCT07914933

• Sleep problems in PAH patients: how sleep breathing relates to PAH outcomes

  This study tests how sleep-disordered breathing and nocturnal oxygen changes relate to outcomes in adults with pulmonary arterial hypertension.

  Recruiting Chinese Pulmonary Vascular Disease Research Group · Beijing · NCT07852403

• Treprostinil inhalation powder for PAH patients switching from selexipag

  This study tests whether inhaled treprostinil (LIQ861) is safe and tolerable for adults with PAH who are moving from oral selexipag to inhaled therapy.

  Recruiting Phase 4 Liquidia Technologies, Inc. · Columbus, Georgia · NCT07759804

• Escalation options for PAH patients already on dual therapy

  This trial tests whether adding a prostacyclin pathway drug or increasing sildenafil dose helps PAH patients at intermediate-to-high risk who aren’t at low risk despite dual therapy.

  Recruiting Phase 4 University of Sao Paulo General Hospital · São Paulo, São Paulo · NCT07713914

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.